| scholarly article | Q13442814 |
| P2093 | author name string | E J Collins | |
| B Scott | |||
| B W Robinson | |||
| R A Lake | |||
| B F Kinnear | |||
| A L Marzo | |||
| J J Frelinger | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 6047-55 | |
| P577 | publication date | 2000-12-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity | |
| P478 | volume | 165 |
| Q57227348 | A helpers' guide to infection |
| Q33849643 | A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia |
| Q37376346 | A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer |
| Q42362935 | Adjuvant IL-7 potentiates adoptive T cell therapy by amplifying and sustaining polyfunctional antitumor CD4+ T cells |
| Q39903491 | Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model |
| Q28386603 | Adoptive transfer of Mammaglobin-A epitope specific CD8 T cells combined with a single low dose of total body irradiation eradicates breast tumors |
| Q35210008 | Adoptive-cell-transfer therapy for the treatment of patients with cancer |
| Q26749451 | Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer |
| Q35071850 | Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells |
| Q40169518 | Allogeneic HLA-matched donor dendritic cells loaded with patient leukemic blasts preferentially induce CD4-positive leukemia-reactive donor lymphocytes |
| Q35875288 | Anti-carcinoembryonic antigen immunity. |
| Q37273469 | Antibodies designed as effective cancer vaccines. |
| Q47142436 | Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma |
| Q45406609 | Antitumor activity of dual-specific T cells and influenza virus |
| Q40398670 | Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. |
| Q35091441 | Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma |
| Q83948186 | Association of the 19S proteasomal ATPases with the ATPase-binding domain of CIITA is essential for CIITA stability and MHC class II expression |
| Q64960247 | Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells. |
| Q80234742 | Basic overview of current immunotherapy approaches in urologic malignancy |
| Q64260954 | Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity |
| Q36446446 | Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming |
| Q34041058 | Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help |
| Q45172692 | CD4+ T cell epitope affinity to MHC II influences the magnitude of CTL responses elicited by DNA epitope vaccines |
| Q42385826 | CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes |
| Q79713235 | CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes |
| Q38710453 | CD4+ and CD8+ T cells are both needed to induce paraneoplastic neurological disease in a mouse model |
| Q24540429 | CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. |
| Q37698219 | Cancer vaccine by fusions of dendritic and cancer cells |
| Q45874423 | Canine Parvovirus ns1 gene and Chicken Anemia vp3 gene induce partial oncolysis of Canine Transmissible Venereal Tumor |
| Q38700706 | Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model |
| Q34934320 | Chemoimmunotherapy targeting Wilms' tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer |
| Q36671472 | Clinical significance of immune cell infiltration within gallbladder cancer |
| Q40435764 | Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy |
| Q36567697 | Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer |
| Q80148689 | Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals |
| Q37760422 | Cross-priming in health and disease. |
| Q36399636 | Cytolytic CD8+ T cells recognizing CFP10 are recruited to the lung after Mycobacterium tuberculosis infection |
| Q37991701 | Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects |
| Q42949404 | DNA fusion gene vaccination mobilizes effective anti-leukemic cytotoxic T lymphocytes from a tolerized repertoire |
| Q35210348 | DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency |
| Q36983599 | Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses |
| Q38994017 | Dendritic Cells and Cancer Immunity. |
| Q78840786 | Dendritic cell KLH loading requirements for efficient CD4+ T-cell priming and help to peptide-specific cytotoxic T-cell response, in view of potential use in cancer vaccines |
| Q34661797 | Dendritic cell-based vaccines: barriers and opportunities |
| Q87335130 | Developing effective tumor vaccines: basis, challenges and perspectives |
| Q40230085 | Development of autologous cytotoxic CD4+ T clones in a human model of B-cell non-Hodgkin follicular lymphoma |
| Q36474422 | Effects of depression on parameters of cell-mediated immunity in patients with digestive tract cancers |
| Q46853464 | Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model |
| Q56897802 | Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination |
| Q35234948 | Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. |
| Q40673826 | Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. |
| Q46479328 | Ex vivo priming of CD4 T cells converts immunological tolerance into effective antitumor immunity in a murine model of acute lymphoblastic leukemia |
| Q34803707 | Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy |
| Q36031036 | Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy |
| Q45887207 | HER2 peptide-specific CD8(+) T cells are proportionally detectable long after multiple DNA vaccinations |
| Q57158932 | HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells |
| Q54690022 | HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients. |
| Q37790599 | Harnessing the immune response to treat cancer |
| Q90573204 | High GILT Expression and an Active and Intact MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma |
| Q40449413 | IL-1βR-dependent priming of antitumor CD4(+) T cells and sustained antitumor immunity after peri-tumoral treatment with MSU and mycobacteria. |
| Q37485130 | IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors |
| Q39768951 | IL-7 is superior to IL-2 for ex vivo expansion of tumour-specific CD4(+) T cells |
| Q37078985 | IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells. |
| Q35628806 | Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells |
| Q33496761 | Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells |
| Q37160648 | Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells |
| Q40234190 | Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors |
| Q37319028 | Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells |
| Q40353574 | Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. |
| Q35982675 | Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization |
| Q45086471 | Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma. |
| Q57227353 | Immunology: A helpers' guide to infection |
| Q37012876 | Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients |
| Q26852388 | Immunotherapy for prostate cancer: recent developments and future challenges |
| Q37130575 | In vitro differentiation of adult bone marrow progenitors into antigen-specific CD4 helper T cells using engineered stromal cells expressing a notch ligand and a major histocompatibility complex class II protein |
| Q40598793 | Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber |
| Q42879333 | Induction of Homologous Rather than Heterologous Antigen-Specific CD4 T Cell Responses Is Critical for Functional CD8 T Cell Responses in Mice Transgenic for a Foreign Antigen |
| Q40639503 | Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells |
| Q40007363 | Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. |
| Q64378294 | Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design |
| Q40628602 | Intratumor CpG-Oligodeoxynucleotide Injection Induces Protective Antitumor T Cell Immunity |
| Q41298234 | Intratumoral accumulation of podoplanin-expressing lymph node stromal cells promote tumor growth through elimination of CD4+ tumor-infiltrating lymphocytes |
| Q34700552 | LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems |
| Q34009436 | Langerhans cells as targets for immunotherapy against skin cancer. |
| Q33914233 | Large T Antigen-Specific Cytotoxic T Cells Protect Against Dendritic Cell Tumors through Perforin-Mediated Mechanisms Independent of CD4 T Cell Help |
| Q82695622 | MHC class II expression in pancreatic tumors: a link to intratumoral inflammation |
| Q90911743 | MHC-II neoantigens shape tumour immunity and response to immunotherapy |
| Q55473891 | Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation. |
| Q57297479 | Mesothelin-family proteins and diagnosis of mesothelioma |
| Q27639095 | Minor structural changes in a mutated human melanoma antigen correspond to dramatically enhanced stimulation of a CD4+ tumor-infiltrating lymphocyte line |
| Q36887852 | Molecular profiling of tumor-specific TH1 cells activated in vivo. |
| Q28248444 | Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester |
| Q33730129 | Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. |
| Q37945303 | Naive, effector and memory CD8 T-cell trafficking: parallels and distinctions |
| Q40063602 | Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity. |
| Q87656028 | Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia |
| Q36249440 | Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy |
| Q35116475 | Possible role of arginase-1 in concomitant tumor immunity |
| Q51973490 | Potent CTL induction by a whole cell pertussis vaccine in anti-tumor peptide immunotherapy. |
| Q37000845 | Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells |
| Q89457621 | Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome |
| Q41429144 | Prognostic impact of the tumor-infiltrating regulatory T-cell (Foxp3+)/activated cytotoxic T lymphocyte (granzyme B+) ratio on resected left-sided pancreatic cancer |
| Q33798257 | Rad52 deficiency decreases development of lung squamous cell carcinomas by enhancing immuno-surveillance |
| Q36399807 | Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression |
| Q37118177 | Reengineering dendritic cell-based anti-cancer vaccines |
| Q41592003 | Restoration of defective cross-presentation in tumors by gemcitabine. |
| Q34732491 | Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses |
| Q27310303 | Specific medicinal plant polysaccharides effectively enhance the potency of a DC-based vaccine against mouse mammary tumor metastasis |
| Q35799065 | Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen |
| Q33530527 | T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies |
| Q77148436 | T helper cells, IL-2 and the generation of cytotoxic T-cell responses |
| Q21131200 | TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu |
| Q80404457 | TLR7 stimulation augments T effector-mediated rejection of skin expressing neo-self antigen in keratinocytes |
| Q39003293 | Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death |
| Q38077405 | Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine. |
| Q38120535 | Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy |
| Q58689503 | The Roles of CD4+ T Cells in Tumor Immunity |
| Q34956078 | The T-cell response in patients with cancer |
| Q36382255 | The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer. |
| Q40291259 | The autophagy machinery restrains iNKT cell activation through CD1D1 internalization |
| Q37474735 | The diverse roles of the TNF axis in cancer progression and metastasis |
| Q47131441 | The immunomodulatory activities of licorice polysaccharides (Glycyrrhiza uralensis Fisch.) in CT 26 tumor-bearing mice |
| Q92633429 | The making and function of CAR cells |
| Q38026924 | The use of agonistic anti-CD40 therapy in treatments for cancer |
| Q37317178 | Therapeutic immunity by adoptive tumor-primed CD4(+) T-cell transfer in combination with in vivo GITR ligation |
| Q50957786 | Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication. |
| Q36349514 | Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy |
| Q45775114 | Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. |
| Q92188206 | Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer |
| Q28236025 | Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation |
| Q34022415 | Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. |
Search more.